Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates *Pseudomonas aeruginosa*–induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways

Yuanyuan Hou\(^a,b\), Yan Nie\(^a,b\), Binfeng Cheng\(^a,b\), Jin Tao\(^a,b\), Xiaoyao Ma\(^a,b\), Min Jiang\(^a,b\), Jie Gao\(^a,b\), Gang Bai\(^a,b,\ast\)

\(^a\)State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin 300071, China
\(^b\)Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China

Received 25 November 2015; received in revised form 4 February 2016; accepted 22 February 2016

**Key Words**

Anti-inflammatory; Network pharmacology; Pathogenic bacterial infection; PI3K/AKT pathway; Ras/MAPK pathway; Lung; Mouse

**Abstract**

Gram-negative pathogen–induced nosocomial infections and resistance are a most serious menace to global public health. *Qingfei Xiaoyan Wan* (QF), a traditional Chinese medicine (TCM) formula, has been used clinically in China for the treatment of upper respiratory tract infections, acute or chronic bronchitis and pulmonary infection. In this study, the effects of QF on *Pseudomonas aeruginosa*–induced acute pneumonia in mice were evaluated. The mechanisms by which four typical anti-inflammatory ingredients from QF, arctigenin (ATG), cholic acid (CLA), chlorogenic acid (CGA) and sinapic acid (SPA), regulate anti-inflammatory signaling pathways and related targets were investigated using molecular biology and molecular docking techniques. The results showed that pretreatment with QF significantly inhibits the release of cytokines (TNF-\(\alpha\) and IL-6) and chemokines (IL-8 and RANTES), reduces leukocytes recruitment into inflamed tissues and ameliorates pulmonary edema and necrosis. In

---

**Abbreviations:** ATG, arctigenin; CGA, chlorogenic acid; CLA, cholic acid; Dex, dexamethasone; DMSO, dimethylsulfoxide; ELISA, enzyme-linked immunosorbent assay; ESI, electrospray ionization; GA, genetic algorithm; HE, hematoxylin and eosin; KEGG, Kyoto Encyclopedia of Genes and Genomes; LB, Luria–Bertani; LEV, levofloxacin; MAPK, mitogen activated protein kinase; NFATc1, nuclear factor of activated T cells c1; Ninj1, ninjurin1; PBS, phosphate-buffered saline; PI3K, phosphoinositide 3-kinase; QF, Qingfei Xiaoyan Wan; SARS, severe acute respiratory syndrome; SPA, sinapic acid; TCM, traditional Chinese medicine; TTBS, Tween 20/Tris-buffered saline; UPLC, ultra-performance liquid chromatography

*Corresponding author.

E-mail address: gangbai@nankai.edu.cn (Gang Bai).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

http://dx.doi.org/10.1016/j.apsb.2016.03.002

2211-3835 © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

It may be a challenge to clarify traditional Chinese medicine (TCM) therapies because their mechanisms are usually unclear and many ingredients in these herbal formulas may exert their effects by regulating multiple pathways and targets. Recently, TCM has been considered to target highlights in interconnected pathways that can be used to cure complex disease. The integration of TCM and “network” pharmacology provides an innovative approach for TCM theory of both reductionist and holistic medicine, and bridges traditional application and modern drug discovery. TCM was widely used for the clinical treatment of infectious diseases for thousands of years in China, and it is based on different philosophies than those of Western medicine, which are based on antibiotics. Now, TCM has also played an important role in the prevention and treatment of diseases, such as severe acute respiratory syndrome (SARS) and acquired pneumonia by mutual regulation of the PI3K/AKT and Ras/MAPK pathways. Overall, TCM alleviates asthma and acquires pneumonia by mutual regulation of the PI3K/AKT and Ras/MAPK pathways to inhibit pathogenic bacterial infections effectively.

2. Materials and method

2.1. Reagents and materials

ATG, SPA, CLA, CGA, arctigenin, deoxycholic acid, glycocholic acid and deoxyglycocholic acid were obtained from Yifang S&T (Tianjin, China). Enzyme-linked immunosorbent assay (ELISA) assay kits of rat TNF-α, IL-6, IL-1β and RANTES, as well as human intracellular proteins (total p38, JNK and ERK), were obtained from Pierce/Endogen Co. (Rockford, Illinois, USA). Human TNF-α was purchased from PeproTech (Rocky Hill, NJ, USA). Dexamethasone (Dex) and levofloxacin (LEV) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Reagents for cell culture were obtained from Gibco BRL Life Technologies (Rockville, MD, USA). The NF-κB luciferase reporter plasmid pGL4.32 and Renilla luciferase reporter vector plasmid pRL-TK were obtained from Promega Co. (Fitchburg, WI, USA). The Lipofectamine 2000 transfection reagent was obtained from Invitrogen (Carlsbad, CA, USA). The anti-IκB-α antibody was obtained from Santa Cruz Biotechnology (San Diego, CA, USA). The P. aeruginosa PAK strain, a clinical isolate from the sputum of a patient suffering from bronchiectasis, was provided by Professor Mingqiang Qiao (College of Life Science, Nankai University, China). All other reagents used in this study were of analytical grade.

2.2. Preparation of QF and drugs

Commercial QF (batch No. 5230139) was donated by Tianjin Zhongxin Pharmaceutical Group Co. Ltd., Darentang Pharmaceutical Factory (Tianjin, China). The QF pills were powdered and suspended in distilled water. The QF suspension and LEV were directly diluted with physiological saline for administration to mice. The QF suspension, Dex, ATG, CLA, CGA and SPA were dissolved in dimethylsulfoxide (DMSO) for in vitro experiments, and the final concentration of DMSO added to the cells was less than 0.1%.

2.3. Animals and drug administration

Kunming mice (male, 18–22 g) were purchased from the Experimental Animal Center of the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Animal treatment and maintenance were performed in accordance with the Principle of Laboratory Animal Care (NIH Publication No. 85–23, revised 1985), and the Animal Ethics Committee of Nankai University approved the experimental protocol. All animals were housed in separate cages with food and water freely available under standard laboratory conditions of 23–26 °C with a 12 h light/12 h dark cycle. Sixty mice were randomly allotted into six groups, including an uninfected control group (Con) and five P. aeruginosa infected groups as follows: model group (Mod), positive control group (LEV) and low/medium/high dose QF groups (QF-L/QF-M/QF-H). LEV (7.5 mg/kg/d) and three doses of LEV were administered by intraperitoneal injection (i.p.) daily for 7 days. All mice were infected by the intratracheal instillation of P. aeruginosa-22 g) were purchased from the Experimental Animal Center of the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Animal treatment and maintenance were performed in accordance with the Principle of Laboratory Animal Care (NIH Publication No. 85–23, revised 1985), and the Animal Ethics Committee of Nankai University approved the experimental protocol. All animals were housed in separate cages with food and water freely available under standard laboratory conditions of 23–26 °C with a 12 h light/12 h dark cycle. Sixty mice were randomly allotted into six groups, including an uninfected control group (Con) and five P. aeruginosa infected groups as follows: model group (Mod), positive control group (LEV) and low/medium/high dose QF groups (QF-L/QF-M/QF-H). LEV (7.5 mg/kg/d) and three doses of LEV were administered by intraperitoneal injection (i.p.) daily for 7 days. All mice were infected by the intratracheal instillation of Pseudomonas aeruginosa–induced acute pneumonia by mutual regulation of the PI3K/AKT and Ras/MAPK pathways. CLA and CGA enhanced the actions of ATG and exhibited synergistic NF-κB inactivation effects possibly via the Ras/MAPK signaling pathway. Moreover, CLA is speculated to target FGFR and MEK firstly. Overall, QF regulated the PI3K/AKT and Ras/MAPK pathways to inhibit pathogenic bacterial infections effectively.

© 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of QF (2, 6 or 18 g/kg/d) were administered orally to the mice for one week before P. aeruginosa challenge.

2.4. P. aeruginosa–induced acute lung inflammation

The acute lung inflammation challenge was performed as previously described. The P. aeruginosa PAK strain was used in the experiments and was grown in Luria-Bertani (LB) medium. When necessary, the PAK strain was cultured in duplicate in LB medium overnight, washed twice with phosphate-buffered saline (PBS), resuspended and diluted to a final concentration of 1 × 10^6 colony-forming units/mL. One week after drug administration, all mice except the control group were challenged with 40 µL of intratracheal PAK suspension (approximately 4 × 10^6 colony-forming units/lung), after anesthetizing (50 mg/kg sodium pentobarbital, i.p.). The control group was administered the same volume of PBS via the same route.

2.5. Histopathological evaluation

Twenty-four hours after P. aeruginosa challenge, mice were anesthetized by sodium pentobarbital (50 mg/kg, i.p.), and blood samples were collected from the retro-orbital cavity. The serum was separated and the supernatant was collected and stored at −20 °C for subsequent testing. The lungs were collected and placed in 10% formalin for at least 1 week. The organs were embedded in paraffin, sectioned and stained with hematoxylin and eosin (HE). True color photographic images of the slices were taken using a light microscope (Olympus CKX41, Japan).

2.6. Cell culture, transfection and NF-κB-luciferase assay

BEAS-2B, a cell line derived from human bronchial epithelial cells, was obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37 °C with 5% CO2 in a humidified incubator. The cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Invitrogen, CA, USA) according to the manufacturer's instructions. The cells were pretreated with drugs before stimulation by human TNF-α, the supernatants were collected for the detection of cytokine and chemokine. Simultaneously, BEAS-2B cells were co-transfected in 96-well plates with the NF-κB luciferase reporter plasmid pGL4.32 and Renilla luciferase reporter vector plasmid pRL-TK at 100 and 9.6 ng per well, respectively. Transfection was performed for 24 h using Lipofectamine 2000 according to the manufacturer's instructions. The cells were pretreated with drugs before stimulation by human TNF-α (10 ng/mL) for 6 h. After stimulation, the cells were washed, lysed and assayed for luciferase activity using the PromegaDual-luciferase reporter assay system according to the manufacturer's instructions as previously reported.

2.7. Chemokine, cytokine and intracellular proteins measurements

Cytokines (TNF-α and IL-6), chemokines (IL-8 and RANTES) and intracellular proteins (total p38, JNK and ERK) in the supernatants of plasma, homogenized lungs, cells or cell lysates were measured using commercial ELISA kits according to the manufacturer's instructions. The absorbance of each sample was measured at 450 nm using a Bio-Rad Model 680 microplate reader. Cytokine, chemokine and intracellular protein levels were determined from standard curves and are expressed in picograms per milliliter.

2.8. Western blot analysis

BEAS-2B cells were washed with ice-cold PBS and lysed using lysis buffer (2% SDS, 10% glycerol, 62.5 mmol/L Tris–HCl buffer, pH 6.8) for 10 min. A total of 30 µg protein from the cell lysates was transferred to nitrocellulose membranes following separation on 10% SDS-PAGE. The membranes were blocked in 5% skim milk solution overnight, incubated with polyclonal anti-IκB-α antibody (1:500) at 4 °C for 4 h and then washed twice with Tween 20/Tris-buffered saline (TTBS). The blots were subsequently incubated with a secondary horseradish peroxidase-conjugated rabbit antibody for 1 h at room temperature and then washed extensively with TTBS. Detection was performed using an enhanced chemiluminescence kit (Amersham Biosciences, Uppsala, Sweden) as described by the manufacturer, followed by autoradiography.

2.9. UPLC/Q-TOF-MS analysis

The quantitative analysis of anti-inflammatory compounds was performed as previously described with slight modifications. A Waters Acquity UPLC System (Waters Co., Milford, MA) equipped with a photodiode array detector and a Waters Q-TOF Premier with an electrospray ionization (ESI) system (Waters MS Technologies, Manchester, UK) was used. The system was controlled using the MassLynx V4.1 software (Waters Co.). An Acquity BEH C18 column (100 mm × 2.1 mm, 1.7 µm, Waters Co.) was used for the separation. The products were eluted on a gradient of 0.1% v/v aqueous formic acid (mobile phase A) and acetonitrile (mobile phase B). The mobile phase gradient was as follows: 5% to 15% B from 0 to 3 min, 15% to 30% B from 3 to 13 min, 30% to 35% B from 13 to 15 min, 35% to 80% B from 15 to 20 min, 80% to 100% B from 20 to 22 min, and 100% to 5% B from 22 to 24 min. The flow was maintained at 5% B from 24 to 30 min. The flow rate was set at 0.4 mL/min, and the column temperature was 30 °C. The experimental conditions for the Q-TOF-MS were the same as previously reported.

2.10. Quantitative real-time PCR

After stimulation by drugs (ATG, CLA, CGA or SPA) and TNF-α, the total RNA was extracted from the BEAS-2B cells with TRIzol (Invitrogen, CA, USA) according to the manufacturer's instructions. The cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA). PCR amplification was performed and analyzed in triplicate using the GoTaqPCR Master Mix (Promega), and the emission intensity from the BRYT Green was detected with an iCycler detection system (Bio-Rad, Hercules, CA, USA). The expression levels of each gene were normalized with the internal reference gene, β-actin. The PCR primers for the Ras/MAPK (p38, Jnk, Erk, Ras and Pkc) and PI3K/AKT pathway (Pitk, Fak and Jak2) were designed and shown in Table 1.

2.11. Target prediction and molecular docking

Anti-inflammatory candidate compounds were selected and their structures were saved in mol2 format file, and placed into the PharmMapper database (http://59.78.96.61/pharmmapper/) for target prediction. Annotation and pathway analysis were performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/). To further evaluate the selectivity of targets, a series of candidate molecules were optimized using
LYMPHOCYTIC INFILTRATION caused capillary congestion, obstruction of small airways by sections of lung tissue of HE staining are shown in Fig. 1A. PAK strain production of cytokines.

3. Results

2.12. Statistical analysis

The data are expressed as the mean ± standard deviation (SD) of at least 3 independent experiments. One-way ANOVA and student's t-test were used for statistical analysis. Differences were considered statistically significant if the P value was less than 0.05.

3. Results

3.1. Effects of QF on pulmonary histopathology and the production of cytokotyes

To evaluate the effects of QF on acute lung inflammation, the cross-sections of lung tissue of HE staining are shown in Fig. 1A. PAK strain infection caused capillary congestion, obstruction of small airways by lymphocytic infiltrates, and widened alveolar septa compared to the structural integrity of the lung tissue in the control group. Pretreatment with medium and high-dose QF significantly reduced histological injury, with less obstruction of small airways and recruitment of inflammatory infiltrates (P < 0.05 and P < 0.01, respectively). However, histological damage was not improved by low-dose QF. The evidence indicated that medium and high-dose QF ameliorated P. aeruginosa-induced lung infection in mice.

3.2. Effects of QF on cytokine activation and IKB-a degradation in bronchial epithelial cells

The effects of QF on the production of cytokines were also studied on bronchial epithelial cells in vitro. Pretreatment for 4 h with different doses of QF (QF-L, 0.1 mg/mL; QF-M, 0.5 mg/mL; QF-H, 2.5 mg/mL) was performed, followed by 10 ng/mL TNF-a stimulation for 6 h. The positive control, Dex (1 μmol/L), and the medium and high-dose QF significantly suppressed IL-6 and IL-8 expression (Fig. 2A, B) and NF-kB activation compared to the model group (P < 0.05 and P < 0.01, Fig. 2C). However, the low dose QF had no inhibitory effect. To verify the effect of QF-mediated inhibition of NF-kB, western blotting was used to determine whether QF inhibited TNF-a-stimulated IKB-a degradation. As shown in Fig. 2D, IKB-a degradation induced by TNF-a is suppressed by QF in a dose-dependent manner. These results demonstrate the anti-inflammatory effects of QF at the cellular level.

3.3. Quantitative analysis of anti-inflammatory ingredients

To clarify the content of the anti-inflammatory ingredients, UPLC/Q-TOF-MS was used to identify the amount of arctiin (ATG-4-glucoside), SPA, CGA and CLA derivatives in QF (Fig. 3). Compared to CGA (2.18 μmol/mL) and SPA (0.35 μmol/mL), the amount of ATG-4-glucoside (29.94 μmol/mL) and total CLA derivatives (50.65 μmol/mL), including CLA (22.09 μmol/mL), deoxycholic acid (11.95 μmol/mL), glycocholic acid (11.94 μmol/mL) and deoxyglycocholic acid (4.67 μmol/mL), are higher in QF. ATG is the primary metabolite after oral administration of arctiin. Therefore, ATG and CLA were predicted to play a major role in the anti-inflammatory process. These compounds were derived from the Fructus Arctii and Bovis Calculus, respectively.

3.4. Effects of four anti-inflammatory ingredients on candidate gene expression

To investigate the possible anti-inflammatory mechanism, the expression of critical genes of the PI3K/AKT and Ras/MAPK pathways that were proved to be effective for QF-H group (data not shown) was determined using quantitative RT-PCR. As shown in Fig. 4, the mRNA expression of p38, Jnk, Erk, Fak, PI3k, Ras, Jak2 and Pkc were up-regulated greatly after TNF-a (10 ng/mL) stimulation for 6 h in the model group. Compared to the model
group, pretreatment for 2 h with ATG inhibited the expression of all genes significantly ($P<0.05$). However, the other compounds had different inhibitory effects. The Ras/MAPK-related gene expression of $p38$, $Erk$ ($P<0.05$) and $Ras$ ($P<0.01$) was significantly decreased with CLA pretreatment. CGA suppressed the expression of $p38$, $Jnk$ ($P<0.05$) and $Pi3k$ ($P<0.01$). Furthermore, SPA inhibited the expression of $p38$, $Jnk$, $Erk$, $Ras$ ($P<0.05$) and $Pi3k$, $Fak$ ($P<0.05$). These results indicated that CLA only affected the Ras/MAPK pathway, but ATG, CGA and SPA affected both the PI3K/AKT and Ras/MAPK pathways.

3.5. Synergistic effects of anti-inflammatory ingredients on PI3K/AKT pathway

PI3K/AKT and Ras/MAPK pathways have similar functions and have complex interactions$^{16}$; $p38$ kinase-dependent MAPK has an activating function for AKT$^{17}$ and PI3K/AKT is activated by low-molecular-weight GTP/GDP binding GTPases, such as Ras, to further regulate the expression of NF-$\kappa$B$^{18}$. To elucidate the synergistic effect on PI3K/AKT/NF-$\kappa$B, the combination treatment of the above four ingredients was detected by downstream NF-$\kappa$B-dependent signal transduction (Fig. 5). Treatment with ATG, CLA, CGA or SPA decreased NF-$\kappa$B dependent transcription ($P<0.05$). When ATG was combined with CLA, CGA and SPA, or all together, the inhibition was greater than for any one drug ($P<0.01$ and $P<0.001$). These results indicate that ATG is the most important inhibitor of the PI3K/AKT pathway.

3.6. Intracellular MAPK proteins levels validation of $p38$, JNK, and ERK

MAPK has three family members, $p38$, JNK and ERK. PI3K inhibitors decrease the activity of the Ras/MAPK pathway$^{19}$. The effects of single or combination treatment with different inhibitors on $p38$, JNK and ERK intracellular proteins levels in TNF-$\alpha$ (10 ng/mL) stimulated BEAS-2B cells were validated by ELISA. As shown in Fig. 6, treatment with ATG alone significantly suppressed the levels of $p38$, $Jnk$, $Erk$ and $Ras$ ($P<0.05$). When ATG was combined with CLA, CGA and SPA, or all together, the inhibition was greater than for any one drug ($P<0.01$ and $P<0.001$). These results indicate that ATG is the most important inhibitor of the PI3K/AKT pathway.
JNK, and ERK ($P < 0.01$). CGA suppressed the expression of p38 and JNK ($P < 0.05$). CLA reduced p38 and ERK ($P < 0.05$) and SPA only down-regulated the p38 level ($P < 0.01$). For paired applications, the synergistic effect of ATG combined with CLA suppressed the p38 and ERK levels ($P < 0.001$), whereas ATG combined with CGA or SPA primarily affected the p38 and JNK levels ($P < 0.001$).

### 3.7 Target docking of active ingredients and anti-inflammatory network analysis

To explore potential protein targets, a pharmacophore matching platform, PharmMapper server, was utilized for target docking in the PI3K/AKT and Ras/MAPK pathways. Molecular docking validation was performed with AutoDock 4.0, providing further detailed information for the representational ligands and regulated targets, including ATG for PDK1 ($-7.24$ kcal/mol) and JNK ($-8.99$ kcal/mol), CLA for FGFR ($-8.16$ kcal/mol) and MEK ($-9.86$ kcal/mol), and CGA for Ras ($-7.16$ kcal/mol), HSPA ($-8.06$ kcal/mol) and Rac ($-6.24$ kcal/mol), which showed higher scores for the PI3K/AKT and Ras/MAPK pathways identifying them as potential targets. However, SPA for PDK1 ($-5.10$ kcal/mol), FGFR ($-5.38$ kcal/mol), Ras ($-4.39$ kcal/mol) and Rac ($-5.21$ kcal/mol) had a lower binding energy and were omitted from further analysis. The detail interaction information of the key targets and related compound is shown in Fig. 7.
Based on the KEGG analysis and the above result, the key anti-inflammatory network for QF and the PI3K/AKT and Ras/MAPK pathways is summarized in Fig. 7.

4. Discussion

P. aeruginosa–induced pneumonia is a complex process. First, large numbers of thalli aggregating in the air way utilize flagellum, fimbriae, and polysaccharides on the membrane surface to adhere to respiratory epithelia. Then, the immune response of the host is activated via invasion of the type III secretory protein, pyocyanin, LPS and other virulence factors. Consequently, cytokines, chemotactic factors and other inflammatory mediators are produced by host cells, which recruit and activate macrophages, neutrophilic granulocytes, and T cells, resulting in severe lung injury and mortality. In this study, we established a mouse acute pneumonia model with P. aeruginosa and the protective effects of QF were estimated by evaluating the expression of inflammatory mediators and the histopathological condition. The results indicate that pretreatment with QF significantly inhibits the release of cytokines (TNF-α, IL-6) and chemokines (IL-8, RANTES), reduces leukocytes recruitment into inflamed tissues, ameliorates pulmonary edema and necrosis, and promotes the survival of mice.

PI3K/AKT and Ras/MAPK are two important pathways for cell membrane receptor signal transduction, which are involved in both the inflammatory and immune responses. LPS activates PKC and initiates pro-inflammatory signals, such as FAK and Ras. FAK, a protein tyrosine kinase, can activate PI3K and MAPK to regulate the expression of cytokines in the immune and inflammatory responses. Furthermore, Ras is a GTPase, which activates ERK and p38 to regulate the generation of inflammatory factors. By contrast, after binding to membrane receptors or activating JAK, cytokines and other growth factor can activate PI3K and MAPKs to regulate the proliferation and differentiation of cells and the expression of pro-inflammatory factors. The pro-inflammatory factor TNF-α is not only a basic factor of the inflammatory response, but it also acts on Gram-negative bacteria through a positive feedback pathway and synergistically enhances the infection.

In this study, cultured BEAS-2B cells induced with TNF-α were selected for the inflammation model to assess the anti-inflammatory effects of QF.
inflammatory effect of QF in vitro. Four candidate compounds from QF were then selected to determine the synergistic anti-inflammatory mechanisms.

ATG is a representative dibenzyl butyrolactone lignan with anti-inflammatory, anti-viral, anti-tumor, and Ca\textsuperscript{2+} antagonist activities\textsuperscript{33}. Its anti-inflammatory mechanisms include suppression of the overproduction of NO by inhibiting the JAK-STAT signal pathway in LPS-stimulated macrophages\textsuperscript{34,35}, inhibition of AKT phosphorylation and amelioration of inflammation by inhibiting the PI3K/AKT pathway\textsuperscript{36,37}, regulation of the activation of MAP kinases, leading to AP-1 inactivation and the production of TNF-\textalpha\textsuperscript{38}. In this study, ATG was predicted target to PDK1 and downregulate the phosphorylation of AKT and PKC, and further affect the expression of the downstream genes, NF-\textkappa\textB and MAP kinases.

CGA significantly inhibits the expression of COX-2 and iNOS, attenuates inflammation-related markers, such as IL-1\beta, TNF-\alpha, IL-6, and ninjurin1 (Ninj1), abolishes the phosphorylation of Akt, p38, ERK, and down regulates a receptor activator of the NF-kB ligand induced nuclear factor of activated T cells c1 (NFATc1) expression\textsuperscript{39,40}. Additionally, the effects of CGA against LPS-induced inflammation may be due to its ability to attenuate the TLR4-mediated NF-\textkappa\textB signaling pathway\textsuperscript{41}. In this study CGA has been suggested to bind to the Ras protein, and when combined with ATG affects the p38 and ERK pathways. These results were consistent with previous reports.

In addition, the mechanism of the anti-inflammatory effects of CLA and SPA for the suppression of TNF-\alpha and IL-1\beta expression via NF-\textkappa\textB was shown in previous studies\textsuperscript{42,43}. In this study, CLA simultaneously targeted the upstream protein FGFR and the downstream protein MEK of the Ras/MAPK pathway, which was speculated firstly. When combined with ATG, the effect also occurred on the p38 and ERK sub-pathway. SPA has a smaller molecular structure and the binding activities were also weaker. Furthermore, because of its low content, SPA did not play a major role in the overall anti-inflammatory effect.

In summary, a network mechanism of several ingredients was identified from QF and mutual suppression was demonstrated on the regulation of primary intracellular immune response to ameliorate acute pneumonia induced by \textit{P. aeruginosa}. ATG was the principal ingredient responsible for the anti-inflammatory effect both on the PI3K/AKT and Ras/MAPK pathways. The other ingredients, CLA, and CGA, enhanced the

**Figure 6** Effects of anti-inflammatory compounds from QF on the intracellular protein expressions of (A) p38, (B) JNK, and (C) ERK in BEAS-2B cells. ATG, CLA, CGA, and SPA were administered at 50 \textmu mol/L when used alone, 25 \textmu mol/L for paired combinations, and 12.5 \textmu mol/L for combinations of 4 drugs. The cells were lysed after drug and TNF-\alpha stimulation, and the cell lysates were analyzed by ELISA for p38, JNK, and ERK levels. The values shown are mean \pm SD of 6 independent experiments; *\textsuperscript{P}<0.05, **\textsuperscript{P}<0.01 and ***\textsuperscript{P}<0.001 vs. group treated with TNF-\alpha in the absence of drugs (n=6).

**Figure 7** The scheme of the proposed network anti-inflammatory mechanisms for QF in the PI3K/AKT and Ras/MAPK pathways.
actions of ATG and showed synergistic NF-κB inactivation effects, possibly via the Ras/MAPK signal pathway.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81173638 and 81373506) and the Key Program of Natural Science of Foundation of Tianjin, China (No.13JCZDJC31400).

References

1. Normile D. The new face of traditional Chinese medicine. Science 2003;299:188–90.
2. Liu CX, Liu R, Fan HR, Xiao XF, Chen XP, Xu HY, et al. Network pharmacology bridges traditional application and modern development of traditional Chinese medicine. Chin Herb Med 2015;7:3–17.
3. Li S. Mapping ancient remedies: applying a network approach to traditional Chinese medicine. Science 2015;350:S72–4.
4. Xutian S, Cao DY, Wozniak J, Junion J, Boisvert J. Comprehension of the unique characteristics of traditional Chinese medicine. Am J Chin Med 2012;40:231–44.
5. Chen Y, Guo JJ, Healy DP, Zhan S. Effect of integrated traditional Chinese medicine and Western medicine on the treatment of severe acute respiratory syndrome: a meta-analysis. Pharm Pract 2007;5:1–9.
6. Liu Q, Lu L, Hua ML, Xu Y, Xiong HR, Hou W, et al. Jiawei-qingfei-xiaoyanwan: the characterization of ATG and showed synergistic NF-κB inactivation effects, possibly via the Ras/MAPK signal pathway.

10. Bai F, Xu HJ, Zhang Q, Qi XZ, Mou R, Bai G, et al. Functional

17. Rane MJ, Coxon PY, Powell DW, Webster R, Klein JB, Pierce W, et al. P38 kinase-dependent MAPKAPK2 activation functions as 3-phosphoinositide-dependent kinase-2 for AKT in human neutrophils. J Biol Chem 2001;276:3517–23.

18. Lin HH, Chen JH, Chou FP, Wang CJ. Protecotoachic acid inhibits cancer cell metastasis involving the down-regulation of Ras/Ado/NF-κB pathway and MMP-2 production by targeting RhoB activation. Br J Pharmacol 2011;162:237–54.

19. Steelman LS, Pohoretn SC, Shelton JG, Franklin RA, Bertrand FE, McBryde JA. JAK/STAT, Raf/MEK/ERK, PI3K/akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189–218.

20. Stover CK, Pham QX, Erwin AL, Mizoguchi SD, Waller P, Hickey MJ, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;406:559–64.

21. Gellaty SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 2013;67:150–73.

22. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351–68.

23. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, Engel JN, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002;30:521–8.

24. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005;171:1209–23.

25. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807–69.

26. Zhang YP, Cardell LO, Edvinsson L, Xu CB. MAPK/NF-κB-dependent upregulation of kinin receptors mediates airway hyperreactivity: a new perspective for the treatment. Pharmacol Res 2013;71:9–18.

27. Diaz-Meco MT, Moscat J. The atypical PKCs in inflammation: NF-κB and beyond. Immunol Rev 2012;246:154–67.

28. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2013;1830:1–21.

29. Schlaepfer DD, Hou SH, Lim ST, Tomar A, Yu HG, Lim Y, et al. Tumor necrosis factor-α stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. J Biol Chem 2007;282:17450–90.

30. Johnson DS, Chen YH. Ras family of small GTPases in immunity and beyond. Pharmacol Res 2012;66:458–63.

31. Tripathi A, Sodhi A. Growth hormone-induced production of cytokines in murine peritoneal macrophages in vitro: role of JAK/STAT, PI3K, PKC and MAP kinases. Immunobiology 2009;214:430–40.

32. Gosselin D, DeSantis J, Boudé M, Skarme M, Mateou C, Radzioch D. Role of tumor necrosis factor-α in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:327–8.

33. Kang HS, Lee YJ, Kim CJ. Anti-inflammatory activity of arctigenin from Forsythia Fructus. J Ethnopharmacol 2008;116:305–12.

34. Kou XJ, Qi SM, Dai WX, Luo L, Yin ZM. Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells and inhibits the LPS-induced production of cytokines in human primary macrophages. Chin Med 2003;295:351–60.

35. Lampinen M, Carlson M, Häkansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004;59:793–805.

36. He F, Dou DQ, Sun Y, Zhu L, Xiao HB, Kang TG. Plasma pharmacokinetics and tissue distribution of actinid and its main metabolite in rats by HPLC-UV and LC-MS. Planta Med 2012;78:800–6.

37. Lee Jr JT, McBryde JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002;16:486–507.

38. Cho MK, Jang YP, Kim YC, Kim SG. Arctigenin, a phenylpropanoid dibenzyl butyrolactone lignan, inhibits MAP kinases and AP-1
activation via potent MKK inhibition: the role in TNF-α inhibition. *Int Immunopharmacol* 2004;4:1419–29.

39. Kwak SC, Lee C, Kim JY, Oh HM, So HS, Lee MS, et al. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor-κB ligand–induced nuclear factor of activated T cells c1 expression. *Biol Pharm Bull* 2013;36:1779–86.

40. Hwang SJ, Kim YW, Park Y, Lee HJ, Kim KW. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells. *Inflamm Res* 2014;63:81–90.

41. Gao RF, Fu YH, Wei ZK, Zhou ES, Li YM, Yao MJ, et al. Chlorogenic acid attenuates lipopolysaccharide-induced mice mastitis by suppressing TLR4-mediated NF-κB signaling pathway. *Eur J Pharmacol* 2014;729:54–8.

42. Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, et al. Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygenase-2, and proinflammatory cytokines expressions via nuclear factor-κB inactivation. *J Agric Food Chem* 2008;56:10265–72.

43. Hua Q, Zhu XL, Li PT, Liu Y, Zhang N, Xu Y, et al. The inhibitory effects of cholalic acid and hyodeoxycholalic acid on the expression of TNFα and IL-1β after cerebral ischemia in rats. *Arch Pharm Res* 2009;32:65–73.